A paper on TOOsonix treatment of Actinic Keratosis has just been published by the dermatology department at Inselspital Bern in Karger Dermatology, a medical journal with one of the highest impact factors (5.4) in the field of dermatology.
Actinic Keratosis (AK) is the most common precancerous condition in humans, affecting more than 100 million people in USA and EU alone. Finding safe, efficient, quick, pain-reduced and cost-effective treatment modalities are therefore becoming more and more important.
Results show an excellent 72.2% of the treated areas with full resolution of the condition after a single session lasting only about one minute, and without any pre- or post-procedure treatment. A further 14.8% and 11.1% experienced partial-to-complete or partial response respectively. An overall improvement in the condition after a single treatment session was thus observed in 98.1% of the cases. No adverse events were reported.
See the paper here.
